Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chronic Cough AND Cough

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    280 result(s) found for: Chronic Cough AND Cough. Displaying page 3 of 14.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-004041-17 Sponsor Protocol Number: XEN-D0501-CL-05 Start Date*: 2013-12-13
    Sponsor Name:Xention Limited
    Full Title: A double-blind, randomised, placebo-controlled, crossover study to assess the efficacy of XEN-D0501, a TRPV1 antagonist, in reducing the frequency of cough in patients with chronic obstructive pulm...
    Medical condition: Chronic Obstructive Pulmonary Disease.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-021642-22 Sponsor Protocol Number: VR1114693 Start Date*: 2011-04-01
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A two part study to investigate the pharmacokinetics and pharmacodynamics of SB705498, a TRPV1 antagonist, in cough. Part A: an open label study in healthy subjects to determine the exposure to SB-...
    Medical condition: Chronic cough
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10066656 Chronic cough LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004102-13 Sponsor Protocol Number: AcadMed CTU210406 Start Date*: 2006-10-16
    Sponsor Name:Hull and east yorkshire Hospitals Trust
    Full Title: An 8 week, non-selected, cohort, study to investigate whether the treatment of reflux induced cough alters associated bronchial hyperresponsiveness.
    Medical condition: Bronchial hyper-responsiveness in relation to reflux associated chronic cough
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011233 Coughing and associated symptoms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002321-29 Sponsor Protocol Number: MK-7264-042 Start Date*: 2020-02-26
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
    Full Title: A Phase 3b Randomized Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Women with Chronic Cough and Stress Urinary Incontinence
    Medical condition: Chronic Cough and Stress Urinary Incontinence
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10066656 Chronic cough LLT
    20.0 10038359 - Renal and urinary disorders 10066218 Stress urinary incontinence PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-004744-31 Sponsor Protocol Number: TR12 Start Date*: 2019-06-24
    Sponsor Name:Trevi Therapeutics, Inc.
    Full Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis With Nalbuphine ER Tablets for the Treatment ...
    Medical condition: Treatment of Cough in Idiopathic Pulmonary Fibrosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-000580-24 Sponsor Protocol Number: Start Date*: 2019-05-17
    Sponsor Name:Hull & East Yorkshire Hospitals NHS trust
    Full Title: A single arm, open-label clinical trial of azithromycin in pulmonary sarcoidosis
    Medical condition: Sarcoidosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002938-20 Sponsor Protocol Number: 13031 Start Date*: 2013-11-08
    Sponsor Name:University of Nottingham
    Full Title: An open label trial of azithromycin in chronic productive cough
    Medical condition: The medical condition that will be investigated is that of chronic productive cough (with or without a diagnosis of asthma but without a diagnosis of bronchiectasis, smoking related chronic bronchi...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012505-18 Sponsor Protocol Number: nexiam2009 Start Date*: 2009-07-02
    Sponsor Name:UZLeuven [...]
    1. UZLeuven
    2. UZLeuven
    Full Title: A randomized double-blind placebo controlled trial evaluating the effect of esomeprazole (nexiam) 40 mg twice daily in subjects with chronic unexplained cough
    Medical condition: gastroesophageal reflux and chronic cough
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018203 GERD LLT
    9.1 10066656 Chronic cough LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004748-27 Sponsor Protocol Number: Acadmed CTU01/05 Start Date*: 2005-02-21
    Sponsor Name:Hull and east Yorkshire Hospitals Trust, Research and Deveopment, admin porta cabin
    Full Title: An 8 week, double-blind, randomised, parallel group study to investigate the effect of 20 mg Esomeprazole (Nexium) tablets Twice daily versus placebo on symptoms associated with chronic cough due ...
    Medical condition: We will be using Nexium to treat gastro-oesophageal reflux and in return this will reduce reflux related cough ( a manifestation of reflux)
    Disease: Version SOC Term Classification Code Term Level
    3 10013946 2
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004463-39 Sponsor Protocol Number: 221921 Start Date*: 2019-03-06
    Sponsor Name:Sahlgrenska University Hospital, Department of Internal Medicine/Respiratory Medicine and Allergology [...]
    1. Sahlgrenska University Hospital, Department of Internal Medicine/Respiratory Medicine and Allergology
    2. University of Gothenburg
    Full Title: Influence on cough and airway symptoms by oral capsaicin (capscium oleoresin ) – a phase II, randomised, placebo-controlled clinical study in patients with chronic idiopathic cough
    Medical condition: Chronic idiopathic cough
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004715-37 Sponsor Protocol Number: M-34273-46 Start Date*: 2015-04-09
    Sponsor Name:AstraZeneca AB; Karlebyhus, Astraallén, Södertälje SE-151 85, Sweden
    Full Title: A randomised, double blind, placebo controlled, parallel study to assess the benefits of aclidinium bromide in the relief of COPD symptoms including cough when administered to patients with COPD
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-000571-20 Sponsor Protocol Number: D9180C00002 Start Date*: 2020-10-09
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Dise...
    Medical condition: Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) DK (Completed) HU (Completed) NL (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2018-002563-25 Sponsor Protocol Number: IJG-AB4T-2018 Start Date*: 2018-11-15
    Sponsor Name:IDIAP Jordi Gol
    Full Title: Effectiveness of antitussive, anticholinergic and honey therapy versus usual practice in adults with uncomplicated acute bronchitis [AB4T study]
    Medical condition: Cough in the context of acute bronchitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10006451 Bronchitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000418-20 Sponsor Protocol Number: D1450C00001 Start Date*: 2006-04-06
    Sponsor Name:AstraZeneca AB
    Full Title: A 4-week randomized, double-blind, placebo controlled, parallel group, phase II study to assess the efficacy and safety of gefitinib tablets, 250 mg once daily (OD), in adult patients with moderate...
    Medical condition: Moderate Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) FI (Prematurely Ended) NO (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005452-41 Sponsor Protocol Number: DPM-B-301 Start Date*: 2006-05-26
    Sponsor Name:Pharmaxis UK Limited
    Full Title: A phase III Multicenter, randomised, parallel, placebo-controlled, double-blind study to investigate the safety and efficacy of treatment with Bronchitol (dry powder mannitol) in the symptomatic tr...
    Medical condition: Bronchiectasis
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003742-15 Sponsor Protocol Number: 1219.4 Start Date*: 2008-09-10
    Sponsor Name:Boehringer Ingelheim France
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of four weeks treatment of 7.5 mg b.i.d, 15 mg q.d and 15 mg b.i.d. BIBW 2948 BS (inhalation...
    Medical condition: Patients with a diagnosis of Chronic Obstructive Pulmonary Diease associated with chronic bronchitis. Patients must be in stable condition and current or ex-smoher.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003197-28 Sponsor Protocol Number: CQBW251B2201 Start Date*: 2019-08-02
    Sponsor Name:Novartis Pharma AG
    Full Title: A 24-week multi-center, double-blind, placebo controlled dose range finding study to investigate the efficacy and safety of oral QBW251 in COPD patients on triple inhaled therapy (LABA/LAMA/ICS)
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10029972 Obstructive airways disease (chronic) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) NL (Completed) BE (Completed) DK (Completed) FR (Completed) AT (Completed) CZ (Completed) GR (Completed) HU (Completed) IT (Completed) ES (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-004219-37 Sponsor Protocol Number: P000554 Start Date*: 2021-03-16
    Sponsor Name:Universitätsklinikum Freiburg, Leitender Ärztlicher Direktor [...]
    1. Universitätsklinikum Freiburg, Leitender Ärztlicher Direktor
    2. Universitätsklinikum Freiburg, Kaufmännische Direktorin
    Full Title: A randomized, prospective, multicenter, controlled and double-blinded Phase II Clinical Trial to evaluate the influence of inhaled Aviptadil on Cough and Quality of Life in Sarcoidosis patients
    Medical condition: Pulmonary sarcoidosis associated with cough
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037430 Pulmonary sarcoidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002441-18 Sponsor Protocol Number: D6582C00001 Start Date*: 2022-10-27
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIa Randomised, Double-Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    26.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) ES (Ongoing) NL (Completed) IT (Completed) BG (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003937-42 Sponsor Protocol Number: BY217/M2-124 Start Date*: 2005-06-16
    Sponsor Name:ALTANA Pharma AG
    Full Title: Effect of roflumilast on exacerbation rate in patients with COPD A 52 weeks, double-blind study with 500 mcg roflumilast once daily versus placebo
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010952 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 06:46:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA